Skip to content
Menu

aTyr Pharma, Inc. ATYR

Full chart Compare
Set alert

Price alert · ATYR

All alert types
3.69 USD -0.39 (-9.56%)

Regular-session close

3.70 +0.01 +0.27%

After hours · Nov 19, 4:12 PM ET

3.69 Day range 4.21
3.69 52-week range 44.40
YTD
-88.22%
1 year
-86.33%

5D -2.66 (-41.30%)

456FriMonTueWedThu3.78
Market cap
9.41M
Revenue (ttm)
235.00K
EPS (ttm)
-21.64
Shares out
83.94M
Forward P/E
-4.33
YTD return
-88.22%
1-year return
-86.33%
50-day average
3.17
200-day average
2.14
Volume
80.56K
Avg volume
113.21K
Open
4.10
Previous close
4.08
Day's range
3.69 – 4.21
52-week range
3.69 – 44.40
Beta
1.10
Analysts
Buy
Price target
21.29 (+476.8%)

Key statistics

Enterprise value
228.60M
Price / sales
1221.63
Price / book
3.97
Free cash flow
-41.67M
Total cash
65.99M
Total debt
13.57M
Return on equity
-78.14%
Short % of float
3.41%

Fundamental scorecard

5 of 25 checks passed on ATYR’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ATYR Revenue — quarterly 0
ATYR Net income — quarterly -18.26M
ATYR EPS — quarterly -7.43

Earnings

ATYR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.22-0.23-0.01-4.55%
Aug 13, 2024Jun 1, 2024-0.22-0.23-0.01-4.55%

Upgrades / downgrades

ATYR analyst upgrades and downgrades
DateFirmActionFromTo
Dec 10, 2024HC Wainwright & Co.reitBuyBuy
Dec 3, 2024HC Wainwright & Co.reitBuyBuy
Oct 29, 2024HC Wainwright & Co.reitBuyBuy
Oct 4, 2024Wells Fargoinit—Overweight
Sep 5, 2024Jefferiesinit—Buy
Aug 15, 2024HC Wainwright & Co.reitBuyBuy

About aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ATYR — it syncs with the Stock Master app.

Insider holders

ATYR insider holders
InsiderRelationLatest transactionDateShares held
BROADFOOT JILL MARIEChief Financial OfficerSaleFeb 5, 202420,821
CLARKE JOHN K.DirectorConversion of Exercise of derivative securityApr 25, 202319,797
COUGHLIN TIMOTHY PDirectorPurchaseMay 29, 20240
DENYES NANCYGeneral CounselPurchaseJun 4, 202422,267
GROSS JANE ADirectorConversion of Exercise of derivative securityApr 25, 20236,000
LUCAS SVETLANADirectorConversion of Exercise of derivative securityApr 25, 20236,000

Institution ownership

ATYR institution ownership
Holder% heldSharesValueReported
Federated Hermes, Inc.17.47%14,666,60050.16MSep 29, 2024
FMR, LLC13.54%11,369,42938.88MSep 29, 2024
Vanguard Group Inc3.56%2,987,57810.22MSep 29, 2024
Tikvah Management LLC2.93%2,460,8338.42MSep 29, 2024
Logos Global Management LP2.38%2,000,0006.84MSep 29, 2024
Checkpoint Capital L.P.2.07%1,736,4775.94MSep 29, 2024

Fund ownership

ATYR fund ownership
Holder% heldSharesValueReported
Federated Hermes Kaufmann Fund9.35%7,850,00026.85MJul 30, 2024
Federated Hermes Kaufmann Small Cap Fund7.89%6,620,00022.64MJul 30, 2024
Fidelity Growth Company Fund3.44%2,887,9679.88MOct 30, 2024
Fidelity Select Portfolios - Biotechnology3.01%2,524,3948.63MOct 30, 2024
Vanguard Total Stock Market Index Fund2.46%2,065,8357.07MSep 29, 2024
Fidelity Growth Company K6 Fund1.25%1,052,0493.60MOct 30, 2024